Advanced search
Publication Cover
Cancer Investigation Volume 39, 2021 - Issue 3
Submit an article Journal homepage
163
Views
4
CrossRef citations to date
0
Altmetric
Brief Report

Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma

Hannah Robinsona Department of Medicine, Duke University Medical Center, Durham, North Carolina, USACorrespondence[email protected]
,
Michelle Greenb Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
,
Gauri Radkarc Virginia Oncology Associates, Norfolk, Virginia, USA
,
Neal Readyb Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
&
John Stricklerb Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
Pages 235-239 | Received 28 Jan 2021, Accepted 29 Jan 2021, Published online: 15 Feb 2021

References

  • Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15(6):353–365. doi:10.1038/s41571-018-0002-6.
  • Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168(4):584–599. doi:10.1016/j.cell.2016.12.015.
  • Abdelmeguid AS, Bell D, Hanna EY. Sinonasal undifferentiated carcinoma. Curr Oncol Rep. 2019;21(3):26. doi:10.1007/s11912-019-0776-4.
  • Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis. Onco Targets Ther. 2020;13:2491–2510. doi:10.2147/ott.S231257.
  • Chambers KJ, Lehmann AE, Remenschneider A, Dedmon M, Meier J, Gray ST, et al. Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base. 2015;76(2):94–100. doi:10.1055/s-0034-1390016.
  • Workman AD, Brody RM, Kuan EC, Baranov E, Brooks SG, Alonso-Basanta M, et al. Sinonasal undifferentiated carcinoma: a 15-year single institution experience. J Neurol Surg B Skull Base. 2019;80(1):88–95. doi:10.1055/s-0038-1668537.
  • Kuo P, Manes RP, Schwam ZG, Judson BL. Survival outcomes for combined modality therapy for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2017;156(1):132–136. doi:10.1177/0194599816670146.
  • Gelbard A, Hale KS, Takahashi Y, Davies M, Kupferman ME, El-Naggar AK, et al. Molecular profiling of sinonasal undifferentiated carcinoma. Head Neck. 2014;36(1):15–21. doi:10.1002/hed.23267.
  • Dogan S, Chute DJ, Xu B, Ptashkin RN, Chandramohan R, Casanova-Murphy J, et al. Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. J Pathol. 2017;242(4):400–408. doi:10.1002/path.4915.
  • Jo VY, Chau NG, Hornick JL, Krane JF, Sholl LM. Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma. Mod Pathol. 2017;30(5):650–659. doi:10.1038/modpathol.2016.239.
  • Mito JK, Bishop JA, Sadow PM, Stelow EB, Faquin WC, Mills SE, et al. Immunohistochemical detection and molecular characterization of IDH-mutant sinonasal undifferentiated carcinomas. Am J Surg Pathol. 2018;42(8):1067–1075. doi:10.1097/pas.0000000000001064.
  • Takahashi Y, Lee J, Pickering C, Bell D, Jiffar TW, Myers JN, et al. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head Neck. 2016;38 Suppl 1 (Suppl 1):E1926–E1934. doi:10.1002/hed.24350.
  • Finocchiaro G, Toschi L, Gianoncelli L, Baretti M, Santoro A. Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med. 2015;3(6):83. doi:10.3978/j.issn.2305-5839.2015.03.43.
  • AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818–831. doi:10.1158/2159-8290.Cd-17-0151.
  • Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018;2018;(2):1–14. PubMed PMID: 30603737; PubMed Central PMCID: PMCPMC6312096. doi:10.1200/PO.18.00122.
  • Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, et al., for the NCI-MATCH Team. The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst. 2020;112(10):1021–1029. doi:10.1093/jnci/djz245.
  • Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971. doi:10.1056/NEJMoa1406766.
  • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886.
  • Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, et al. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res. 2019;25(24):7312–7319. doi:10.1158/1078-0432.Ccr-19-0994.
  • Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol. 2019;30(12):1985–1991. doi:10.1093/annonc/mdz407.
  • Drilon AE, Camidge DR, Ou SHI, Clark JW, Socinski MA, Weiss J, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). JCO. 2016;34 (15_suppl):108. doi:10.1200/JCO.2016.34.15_suppl.108.
  • Camidge DR, Otterson GA, Clark JW, Ou SHI, Weiss J, Ades S, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. JCO. 2018;36 (15_suppl):9062. doi:10.1200/JCO.2018.36.15_suppl.9062.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.